Skip to Main Content
Try STAT+ TODAY
Trending:
Coronavirus
Pharmalot
STAT+
Health
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Acadia Pharmaceuticals buys pain drug maker, part of effort to expand on psychosis treatment

  • Matthew Herper

By Matthew Herper Aug. 25, 2020

Reprints
Hydroxychloroquine on tray
GEORGE FREY/AFP via Getty Images

Acadia Pharmaceuticals is purchasing a small Texas startup, CerSci, for $52 million in order to acquire a pain drug in the early stages of development, the company said Tuesday.

If the drug succeeds, CerSci could receive an additional $887 million in payments for hitting commercial and development milestones.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Matthew Herper

Matthew Herper

Senior Writer, Medicine, Editorial Director of Events

Matthew covers medical innovation — both its promise and its perils.

Tags

Bluebird wins U.S. approval for a gene therapy to…
Bluebird wins U.S. approval for a gene therapy to treat patients with a rare blood disorder
In an effort to address its missteps during Covid,…
In an effort to address its missteps during Covid, CDC plans an ‘ambitious’ agency overhaul
A complicated fall vaccine campaign: Updated Covid boosters, flu…
A complicated fall vaccine campaign: Updated Covid boosters, flu shots, and how to time the jabs
Bluebird wins U.S. approval for a gene therapy to…
Bluebird wins U.S. approval for a gene therapy to treat patients with a rare blood disorder
‘A blind eye’: NIH fails to ensure clinical trial…
‘A blind eye’: NIH fails to ensure clinical trial results are reported, and still funds researchers…
Virtual Event – Biomarkers: The Foundation of Personalized Oncology
Virtual Event – Biomarkers: The Foundation of Personalized Oncology

Recommended Stories